Capillary and Venous Blood Sampling Devices Market Size & Share, by Blood Collection (Capillary, Venous); Device (Point-Of-Care Testing, Central Testing); Application (Cancer Testing, Heart Disease Testing, Chronic Kidney Disease Testing, HIV/AIDS Testing, Hemoglobin Testing, Glucose Testing, Coagulation Testing); End-user (Hospitals, Clinics, Diagnostic Laboratories) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Growth Drivers

• Rise in Demand for Blood Collection and Transfusions – The rise in demand for blood collection and transfusions is expected to have a positive impact on the capillary and venous blood sampling devices market. Blood transfusions are essential in several medical procedures, including surgeries, cancer treatments, and emergency care. To ensure the safety and effectiveness of blood transfusions and blood donation, blood samples must be collected and tested for compatibility with the recipient's blood type. These devices allow healthcare professionals to collect blood samples quickly and easily, reducing the risk of complications and ensuring the safety and accuracy of the blood samples. For instance, as per the WHO report for 2022, up to 54% of blood transfusions in low-income nations are given to children under the 5 years of age, whereas up to 76% of transfusions in high-income countries are provided to patients over the age of 60.
• Rising application in cancer diagnosis and treatment – There is an increasing application of capillary and venous blood sampling devices in cancer diagnosis and treatment. Developing a leukemia treatment strategy requires a thorough and precise cancer diagnosis as a necessary first step. One of the most crucial methods for diagnosing leukemia in laboratories is blood testing. Capillary and venous blood collection procedures can affect sample quality as well as test result accuracy, emphasizing the necessity for fast, widespread standardization. According to the American Cancer Society, 59,610 new cases of leukemia (of all types) and 23,710 deaths are expected to be estimated in the United States in 2023. There will also be 20,380 new cases of acute myeloid leukemia (AML) and 11,310 fatalities from it.
• Increasing Demand for Apheresis –Apheresis is a medical procedure in which blood is removed from a patient, processed to remove certain components, and then returned to the patient's body. This procedure requires the use of automatic blood collection devices to collect and process the blood. The requirements of Apheresis blood collections differ for women, men, and non-binary donors as different sexes have different total blood volumes (TBV)-even if they weigh the same amount. The standard of care states that only 15% of a person's TBV should be drawn at once.
• Increasing Complexities of Storage and Shipping- Blood products collected using automatic blood collection devices must be compatible with existing storage and shipping systems. If the storage and shipping requirements of blood products change, this can impact the compatibility of these products with existing systems, making it more difficult to integrate automatic blood collection devices into existing workflows. The characteristics of blood samples begin to deteriorate within the hours of collection, if not stored properly. For instance, the FDA states that whole blood (CPDA-1) can be stored at 1-6°C for up to 35 days after the date of collection and the whole blood (ACD, CPD, CP2D) can be stored at 1-6°C for up to 21 days after the date of collection.
• Stringent Regulatory Approval and Product Recall
• Automated Blood Collection Devices are Expensive